Condition

HRD Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 2 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common interventions3

Lead sponsors shown2

Clinical trials

2 shown

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR PathwayNCT06614751 · 2024-11-01

NOT_YET_RECRUITING

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsNCT04826341 · 2021-09-20

COMPLETED

Common interventions

BerzosertibDRUG1 DAT-2645 tabletDRUG1 Sacituzumab GovitecanDRUG1

Leading sponsors

Danatlas Pharmaceuticals Co., Ltd 1 National Cancer Institute (NCI) 1

Trial status mix

COMPLETED1

NOT_YET_RECRUITING1

Phase mix

PHASE12

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.